Bioreductive preparation of ACE inhibitors precursor (R)-2-hydroxy-4-phenylbutanoate esters: Recent advances and future perspectives

Abstract

Optically active (R)-2-hydroxy-4-phenylbutanoate esters ((R)-HPBE) are key precursors for the production of angiotension-converting enzyme (ACE) inhibitors, which are important prescriptive drugs for preventing the formation of angiotensin II and lowering the blood pressure. The biocatalytic asymmetric reduction of ethyl 2-oxo-4-phenylbutanoate (OPBE) to (R)-HPBE with carbonyl reductases has several advantageous attributes, including high enantioselectivity, mild reaction condition, high catalytic efficiency, and environmental benignity. An increasing number of OPBE reductases have been discovered owing to the drastic achievements in genomics, screening and evolution technologies, and process engineering. The potential of (R)-HPBE production process has also been intensively evaluated. This review covers recent progress on the bioreductive preparation of (R)-HPBE, especially on various screening approaches for the identification of OPBE reductases and their characterization.

Keywords

ACE inhibitors / Asymmetric reduction / Reductases / (R)-HPBE

References

[1.] Patel RN. Biocatalysis: Synthesis of chiral intermediates for drugs. Curr Opin Drug Disc Dev, 2006, 9: 741-764.

[2.] Tao JH, Xu JH. Biocatalysis in development of green pharmaceutical processes. Curr Opin Chem Biol, 2009, 13: 43-50.

[3.] Magano J, Dunetz JR. Large-scale carbonyl reductions in the pharmaceutical industry. Org Process Res Dev, 2012, 16: 1156-1184.

[4.] Reetz MT. Biocatalysis in organic chemistry and biotechnology: Past, Present, and Future. J Am Chem Soc, 2013, 135: 12480-12496.

[5.] Iwasaki G, Kimura R, Numao N, Kondo K. A practical and diastereoselective synthesis of angiotensin converting enzyme inhibitors. Chem Pharm Bull, 1989, 37: 280-283.

[6.] Bradshaw CW, Wong CH, Hummel W, Kula MR. Enzyme-catalyzed asymmetric synthesis of (S)-amino-4-phenylbutanoic acid and (R)-2-hydroxy-4-phenylbutanoic acid. Bioorg Chem, 1991, 19: 29-39.

[7.] D’Arrigo P, Pedrocchi-Fantoni G, Servi S. Chemo-enzymatic synthesis of ethyl (R)-2-hydroxy-4-phenylbutyrate. Tetrahedron Asymmetry, 2010, 21: 914-918.

[8.] Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med, 1998, 105: 27S-31S.

[9.] Maruyama S, Nakagomi K, Tomizuka N, Suzuki H. Angiotensin I-converting enzyme inhibitor derived from an enzymatic hydrolysate of casein. II. Isolation and bradykinin-potentiating activity on the ileum of rats. Agric Biol Chem, 1985, 49: 1405-1409.

[10.] Crandall MA (2007) The world cardiovascular drug market, 2^nd edition, Kalorama Information, SKU:KLI1397872.

[11.] Baskar B, Pandian NG, Priya K, Chadha A. Asymmetric reduction of alkyl 2-oxo-4-arylbutanoates and –but-3-enoates by Candida parapsilosis ATCC 7330: assignment of the absolute configuration of ethyl 2-hydeoxy-4-(p-methylphenyl)but-3-enoate by ¹H NMR. Tetrahedron Asymmetry, 2004, 15: 3961-3966.

[12.] Huang SH, Tsai SW. Kinetic resolution of (R, S)-ethyl 2-hydeoxyl-4-phenylbutyrate via lipase-catalyzed hydrolysis and transesterification in isooctane. J Mol Catal B: Enzyme, 2004, 28: 65-69.

[13.] Zhu LF, Meng QH, Fan WZ, Xie XM, Zhang ZG. Direct asymmetric hydrogenation of 2-oxo-4-arylbut-3-enoic acids. J Org Chem, 2010, 75: 6027-6030.

[14.] Aldea R, Alper H. Hydrogenation of the carbonyl group in α-kektoesters and α-ketoamides catalyzed by ruthenium clay. J Org Chem, 1998, 63: 9425-9426.

[15.] Rodrigues JAR, Milagre HMS, Milagre CDF, Moran PJS. A highly enantioselective chemoenzymatic synthesis of syn-3-amino-2-hydroxy esters: Key intermediates of taxol side chain and phenylnorstatine. Tetrahedron Asymmetry, 2005, 16: 3099-3106.

[16.] Meng QH, Zhu LF, Zhang ZG. Highly enantioselective sequential hydrogenation of ethyl 2-oxo-4-arylbut-3-enoate to ethyl 2-hydroxy-4-arylbutyrate. J Org Chem, 2008, 73: 7209-7212.

[17.] Zhang W, Ni Y, Sun ZH, Zheng P, Lin WQ, Zhu P, Ju NF. Biocatalytic synthesis of ethyl (R)-2-hydroxy-4-phenylbutyrate with Candida krusei SW2-26: a practical process for high enantiopurity and product titer. Process Biochem, 2009, 44: 1270-1275.

[18.] Noyori R. Asymmetric catalysis: Science and opportunities. Adv Synth Catal, 2003, 345: 15-32.

[19.] Noyori R, Yamakawa M, Hashiguchi S. Metal-ligand bifuctional catalysis: a nonclassical mechanism for asymmetric hydrogen transfer between alcohols and carbonyl compounds. J Org Chem, 2011, 66: 7931-7944.

[20.] Hall M, Bommarius AS. Enantioenriched compounds via enzyme-catalyzed redox reactions. Chem Rev, 2011, 111: 4088-4110.

[21.] Hollmann F, Arends IWCE, Holtmann D. Enzymatic reductions for the chemist. Green Chem, 2011, 13: 2285-2314.

[22.] Blaser HU, Jalett HP, Wiehl J. Enantioselective hydrogenation of alpha-ketoesters with chinchona-modified platinum catalysts—Effect of acidic and basic solvents and additives. J Mol Catal, 1991, 68: 215-222.

[23.] LeBlond C, Wang J, Liu J, Andrews AT, Sun YK. Highly enantioselective heterogeneously catalyzed hydrogenation of α-ketoesters under mild conditions. J Am Chem Soc, 1999, 121: 4920-4921.

[24.] Schoemaker HE, Mink D, Wubbolts MG. Dispelling the myths—Biocatalysis in industrial synthesis. Science, 2003, 299: 1694-1697.

[25.] Rollin JA, Tamb TK, Zhang PYH. New biotechnology paradigm: Cell-free biosystems for biomanufacturing. Green Chem, 2013, 15: 1708-1719.

[26.] Schmid A, Dordick JS, Hauer B, Kiener A, Wubbolts M, Witholt B. Industrial biocatalysis today and tomorrow. Nature, 2001, 409: 258-268.

[27.] Bai YL, Yang ST. Biotransformation of (R)-2-hydeoxy-4-phenylbutyric acid be D-lactate dehydrogenase and Candida boidinii cells containing formate dehydrogenase coimmbolized in a fibrous bed bioreactor. Biotechnol Bioeng, 2005, 92: 137-146.

[28.] Luetz S, Giver L, Lalonde J. Engineered enzymes for chemical production. Biotechnol Bioeng, 2008, 101: 647-653.

[29.] Behrens GA, Hummel A, Padhi SK, Schaetzle S, Bornscheuer UT. Discovery and protein engineering of biocatalysts for organic synthesis. Adv Synth Catal, 2011, 353: 2191-2215.

[30.] Bommarius AS, Blum JK, Abrahamson MJ. Status of protein engineering for biocatalysts: how to design an industrially useful biocatalyst. Curr Opin Chem Biol, 2011, 15: 194-200.

[31.] Bornscheuer UT, Huisman GW, Kazlauskas RJ, Lutz S, Moore JC, Robins K. Engineering the third wave of biocatalysis. Nature, 2012, 485: 185-194.

[32.] Davids T, Schmidt M, Boettcher D, Bornscheuer UT. Strategies for the discovery and engineering of enzymes for biocatalysis. Curr Opin Chem Biol, 2013, 17: 215-220.

[33.] Oda S, Ohta H. Microbial transformation on interface between hydrophilic carriers and hydrophobic organic solvents. Biosci Biotechnol Biochem, 1992, 56: 2041-2045.

[34.] Oda S, Inada Y, Kobayashi A, Ohta H. Production of ethyl (R)-2-hydroxy-4-phenylbutanoate via reduction of ethyl 2-oxo-4-phenylbutanoate in an interface bioreactor. Biosci Biotechnol Biochem, 1998, 62: 1762-1767.

[35.] de Lacerda PSB, Ribeiro JB, Leite SGF, Ferrara MA, Coelho RB, Bon EPS, da Silva Lima EL, Antunes OAC. Microbial reduction of ethyl 2-oxo-4-phenylbutyrate. Searching for R-enantioselectivity. New access to the enalapril like ACE inhibitors. Tetrahedron Asymmetry, 2006, 17: 1186-1188.

[36.] Chadha A, Manohar M, Soundararajan T, Lokeswari TS. Asymmetric reduction of 2-oxo-4-phenylbutanoic acid ethyl ester by Daucus carota cell cultures. Tetrahedron Asymmetry, 1996, 7: 1571-1572.

[37.] Chen YZ, Lin H, Xu XY, Xia SW, Wang LX. Preparation the key intermediate of angiotensin-converting enzyme (ACE) inhibitors: High enantioselective production of ethyl (R)-2-hydeoxy-4-phenylbutyrate with Candida boidinii CIOC21. Adv Synth Catal, 2008, 350: 426-430.

[38.] He CM, Chang DL, Zhang J. Asymmetric reduction of substituted α- and β-ketoesters by Bacillus pumilus Phe-C3. Tetrahedron Asymmetry, 2008, 19: 1347-1351.

[39.] Dao DH, Okamura M, Akasaka T, Kawai Y, Hida K, Ohno A. Stereochemical control in microbial reduction. Part 31: Reduction of alkyl 2-oxo-4-arylbutyrates by baker’s yeast under selected reaction conditions. Tetrahedron Asymmetry, 1998, 9: 2725-2737.

[40.] Ni Y, Xu JH. Biocatalytic ketone reduction: a green and efficient access to enantiopure alcohols. Biotechnol Adv, 2012, 30: 1279-1288.

[41.] Nakamura K, Yamanaka R, Matsuda T, Harada T. Recent developments in asymmetric reduction of ketones with biocatalysts. Tetrahedron Asymmetry, 2003, 14: 2659-2681.

[42.] Xie Y, Xu JH, Lu WY, Lin GQ. Adzuki bean: a new resource of biocatalyst for asymmetric reduction of aromatic ketones with high stereoselectivity and substrate tolerance. Bioresour Technol, 2009, 100: 2463-2468.

[43.] Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N. Identification of cystic fibrosis gene: Chromosome walking and jumping. Science, 1989, 245: 1059-1065.

[44.] Qiu JG, Yun M, Wen YZ, Chen LS, Wu LF, Liu WP. Functional identification of two novel genes from Pseudomonas sp. strain HZN6 involved in the catabolism of nicotine. Appl Environ Microbiol, 2012, 78: 2154-2160.

[45.] Zhang JD, Li AT, Yang Y, Xu JH. Sequence analysis and heterologous expression of a new cytochrome P450 monooxygenase from Rhodococcus sp for asymmetric sulfoxidation. Appl Microbiol Biotechnol, 2010, 85: 615-624.

[46.] Zhang J, Yin JG, Hang BJ, Cai S, He J, Zhou SG, Li SP. Cloning of a novel arylamidase gene from Paracoccus sp. strain FLN-7 that hydrolyzes amide pesticides. Appl Environ Microbiol, 2012, 78: 4848-4855.

[47.] Ni Y, Li CX, Zhang J, Shen ND, Bornscheuer UT, Xu JH. Efficient reduction of ethyl 2-oxo-4-phenylbutyrate at 620 g/L by a bacterial reductase with broad substrate spectrum. Adv Synth Catal, 2011, 353: 1213-1217.

[48.] Reddy TBK, Thomas AD, Stamatic D, Bertsch J, Isbandi M, Jansson J, Mallajosyula J, Pagani I, Lobos EA, Kyrpides NC (2014) The genomes online database (GOLD) v.5: a metadata management system based on a four level (meta)genome project classification. Nucl Acids Res doi: 10.1093/nar/gku950.

[49.] Wang LJ, Li CX, Ni Y, Zhang J, Liu X, Xu JH. Highly efficient synthesis of chiral alcohols with a novel NADH-dependent reductase from Streptomyces coelicolor. Bioresour Technol, 2011, 102: 7023-7028.

[50.] Itoh N, Morihama R, Wang JC, Okada K, Mizuguchi N. Purification and characterization of phenylacetaldeyde reductase from a styrene-assimilating Corynebacterium strain, ST-10. Appl Environ Microbiol, 1997, 63: 3783-3788.

[51.] Makino Y, Dairi T, Itoh N. Engineering the phenylacetaldehyde reductase mutant for improved substrate conversion in the presence of concentrated 2-propanol. Appl Microbiol Biotechnol, 2007, 77: 833-843.

[52.] Itoh N, Isotani K, Nakamura M, Inoue K, Isogai Y, Makino Y. Efficient synthesis of optically pure alcohols by asymmetric hydrogen-transfer biocatalysis: application of engineered enzymes in a 2-propanol-water medium. Appl Microbiol Biotechnol, 2012, 93: 1075-1085.

[53.] Lavandera I, Kern A, Schaffenberger M, Gross J, Glieder A, Glieder A, de Wildeman S, Kroutil W. An exceptionally DMSO-tolerant alcohol dehydrogenase for the stereoselective reduction of ketones. ChemSusChem, 2008, 1: 431-436.

[54.] Kaluzna IA, Andrew AA, Bonilla M, Martzen MR, Stewart JD. Enantioselective reductions of ethyl 2-oxo-4-phenylbutyrate by Saccharomyces cerevisiae dehydrogenases. J Mol Catal B: Enzymatic, 2002, 17: 101-105.

[55.] Kaluzna IA, Matsuda T, Sewell AK, Stewart JD. Systematic investigation of Saccharomyces cerevisiae enzymes catalyzing carbonyl reductions. J Am Chem Soc, 2004, 126: 12827-12832.

[56.] Richter N, Hummel W. Biochemical characterization of a NADPH-dependent carbonyl reductase from Neurospora crassa reducing α- and β-keto esters. Enzyme Microbial Technol, 2011, 48: 472-479.

[57.] Ni Y, Su YN, Li HD, Zhou JY, Sun ZH. Scalable biocatalytic synthesis of optically pure ethyl (R)-2-hydroxy-4-phenylbutyrate using a recombinant E. coli with high catalyst yield. J Biotechnol, 2013, 168: 493-498.

[58.] Ma HM, Yang LL, Ni Y, Zhang J, Li CX, Zheng GW, Yang HY, Xu JH. Stereospecific reduction of methyl o-chlorobenzoylformate at 300 g · L⁻¹ without additional cofactor using a carbonyl reductase mined from Candida glabrata. Adv Synth Catal, 2012, 354: 1764-1772.

[59.] Shen ND, Ni Y, Ma HM, Wang LJ, Li CX, Zheng GW, Zhang J, Xu JH. Efficient synthesis of a chiral precursor for angiotensin-converting enzyme (ACE) inhibitors in high space-time yield by a new reductase without external cofactors. Org Lett, 2012, 14: 1982-1985.

[60.] Yun HD, Choi HL, Fadnavis NW, Kim BG. Stereosepecific synthesis of (R)-2-hydroxy carboxylic acids using recombinant E. coli BL21 overexpressing YiaE from Escherichia coli K12 and glucose dehydrogenase from Bacillus subtilis. Biotechnol Prog, 2005, 21: 366-371.

[61.] Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, Favia AD, Duarte RG, Jörnvall H, Kavanagh KL, Kedishvili N, Kisiela M, Maser E, Mindnich R, Orchard S, Penning TM, Thornton JM, Adamski J, Oppermann U. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chemico-Biol Interact, 2009, 178: 94-98.

[62.] Hedlund J, Jörnvall H, Persson B. Subdivision of the MDR superfamily of medium chain dehydrogenases/reductases through iterative hidden Markov model refinement. BMC Bioinformatics, 2010, 11: 534-549.

[63.] Hyndman D, Bauman DR, Heredia VV, Penning M. The aldo-keto reductase superfamily homepage. Chemico-Biol Interact, 2003, 143–144: 621-631.

[64.] Hwang CC, Chang YH, Hsu CN, Hsu HH, Li CW, Pon HI. Mechanistic roles of Ser-114, Tyr-155, and Lys-159 in 3-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni. J Biol Chem, 2005, 280: 3522-3528.

[65.] Ehrensberger AH, Wilson DK. Structural and catalytic diversity in the two family 11 aldo-keto reductases. J Mol Biol, 2004, 337: 661-673.

[66.] Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucl Acid Res, 2014, 42: W320-W324.

[67.] Moore JC, Pollard DJ, Kosjek B, Devine PN. Advances in the enzymatic reduction of ketones. Acc Chem Res, 2007, 40: 1412-1419.

[68.] Zhao HM, van der Donk WA. Regeneration of cofactors for use in biocatalysis. Curr Opin Biotechnol, 2003, 14: 583-589.

[69.] Huisman GW, Liang J, Krebber A. Practical chiral alcohol manufacture using ketoreductases. Curr Opin Chem Biol, 2010, 14: 122-129.